Piper Sandler initiated coverage on CinCor Pharma with a new price target
$CINC
Biotechnology: Pharmaceutical Preparations
Health Care
Piper Sandler initiated coverage of CinCor Pharma with a rating of Overweight and set a new price target of $73.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/7/2022 | $22.00 | Overweight | Barclays |
| 11/29/2022 | Outperform → Perform | Oppenheimer | |
| 11/29/2022 | $60.00 → $22.00 | Overweight → Equal-Weight | Morgan Stanley |
| 10/28/2022 | $67.00 | Buy | Goldman |
| 8/22/2022 | $73.00 | Overweight | Piper Sandler |
| 2/1/2022 | Outperform | Evercore ISI | |
| 2/1/2022 | $30.00 | Outperform | Oppenheimer |
| 2/1/2022 | $27.00 | Overweight | Morgan Stanley |
8-K - CinCor Pharma, Inc. (0001868734) (Filer)
25-NSE - CinCor Pharma, Inc. (0001868734) (Subject)
SC 14D9/A - CinCor Pharma, Inc. (0001868734) (Subject)
4 - CinCor Pharma, Inc. (0001868734) (Issuer)
4 - CinCor Pharma, Inc. (0001868734) (Issuer)
4 - CinCor Pharma, Inc. (0001868734) (Issuer)
-- Oversubscribed financing brings together leading syndicate of life sciences investors -- -- Proceeds to support clinical development of first-in-class therapies for neurological disorders – BOSTON, Oct. 30, 2024 /PRNewswire/ -- Axonis Therapeutics, a biotechnology company focused on the development of novel neuromedicines, announced today the successful completion of an oversubscribed $115 million Series A financing. Proceeds from the financing will be used to advance Axonis' lead development candidate, AXN-027, through clinical proof-of-concept in patients. AXN-027 is a first-in-class oral small molecule designed to potentiate the function of KCC2, a major CNS chloride transporter essent
- venBio promotes Yvonne Yamanaka, Ph.D. to Partner venBio today announced the closing of venBio Global Strategic Fund V ("venBio Fund V"), its fifth life sciences venture capital fund, exceeding its target and closing on approximately $528 million in capital commitments in an oversubscribed fundraise. The firm initiated the fundraise for Fund V in mid-April. Limited partners of Fund V include a broad range of institutional investors comprising sovereign wealth funds, corporate pensions, financial institutions, university endowments, medical institutions, foundations, family offices and funds-of-funds. Under the fund leadership of Managing Partners Richard Gaster, M.D., Ph.D., Corey Goo
Trudhesa® Achieved nTRx of Over 18.5K in Q1 2023; Increase of 112% vs. Q1 2022 Trudhesa Net Product Revenue in Q1 2023 Increased 149% vs. Q1 2022 to $4.4 Million Impel to Host Investor Conference Call Today at 8:30 a.m. ET SEATTLE, May 12, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ:IMPL), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today reported financial results for the first quarter ended March 31, 2023 and provided a business update. "Following our strategic reprioritization to focus the company on maximizing the growth potential of
Barclays initiated coverage of CinCor Pharma with a rating of Overweight and set a new price target of $22.00
Oppenheimer downgraded CinCor Pharma from Outperform to Perform
Morgan Stanley downgraded CinCor Pharma from Overweight to Equal-Weight and set a new price target of $22.00 from $60.00 previously